Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shire Japan Takes Aim at $500 Million Sales in 10 Years
October 8, 2014
- Tsumura to Increase Sales of 4 Products in Field of Dermatology by 20% in FY2015
October 8, 2014
- Nipro Pharma Ties Up with Unilab of Philippines as Part of Efforts to Develop Asian Market
October 8, 2014
- Cost-Effective Assessment Could Hamper Patient Access to New Drugs: Chugai CEO
October 7, 2014
- Chugai, Roche Chiefs Were in Talks on Recent Deal Change from 2 Years Ago
October 7, 2014
- Takeda Ordered to Pay Over US$2 Million in Philadelphia Actos Suit
October 7, 2014
- Avigan-Administered French Ebola Patient Recovers
October 7, 2014
- AnGes MG Commences Patient Registration in US for Collategene PIII Study
October 7, 2014
- Januvia Remains No. 1, Trazenta Climbs to No. 2 in GP Market in Anterio’s “Mind Share” Ranking for August
October 6, 2014
- JCR Pharmaceuticals Hopes to Make Japan’s First Cell Product into New Profit Pillar
October 6, 2014
- Takeda Directors Face 3-Month Pay Cut over CASE-J Issue
October 6, 2014
- Daiichi Sankyo Opens Representative Office in Vietnam
October 6, 2014
- Takeda to Invest in Alfresa Corporation’s Vaccine-Related Subsidiary
October 6, 2014
- Eisai Launches Halaven in Australia
October 3, 2014
- Santen Completes Transfer of Ophthalmology Assets from Merck
October 3, 2014
- Jim Murphy, GM of Alcon US Vision Care, Leads Alcon Japan as New President
October 3, 2014
- MTPC Charges Ahead with Research Lab Overhaul to Buttress Drug Discovery
October 2, 2014
- Daiichi Sankyo Seeks Tuberculosis Indication for Cravit, AGs
October 2, 2014
- MTPC Paid 19.8 Billion Yen to Physicians, Medical Institutions in FY2013
October 2, 2014
- Novartis Pharma Notifies PMDA of Additional 1,299 Unreported Serious ADRs
October 2, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…